Eisai files rufinamide for rare epilepsy in Japan after official nudge
This article was originally published in Scrip
Following its identification by the government several years ago as a high-need drug, Eisai has submitted an approval application in Japan for rufinamide for the treatment of Lennox-Gastaut syndrome (LGS).
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.